Developer docs
API playgroundTry for free, no card

Search company profiles

PharmIdea

Full company profile

uuid000oap4

Namestring
PharmIdea
Legal namestring
SIA PHARMIDEA
Websiteurl
pharmidea.lv
Company typeenum
Private
Founded yearint
2010
Descriptiontext

PharmIdea (legal entity SIA PHARMIDEA) is a Latvia-headquartered, privately held pharmaceutical manufacturer and CDMO/CMO that is the only producer of sterile drugs in vials in Latvia. Founded in 2005 with EU GMP certification achieved in 2010, the company has accumulated 15+ years of sterile drug technology development, registration documentation, and manufacturing experience, with regulatory approvals from the European Union plus 14+ additional countries including Saudi Arabia, UAE, South Korea, Canada, Russia, Thailand, Philippines, Malaysia, Kuwait, and Jordan. Its products are registered and distributed in 60+ countries across Europe, Africa, Asia, and the Americas.

The technology stack centers on three sterile manufacturing platforms — lyophilization (freeze-drying), aseptic filling for 2-30 ml vials, and terminal steam sterilization (autoclaving) — supplemented by in-house analytical capabilities (HPLC, UV/VIS spectrophotometry, SCF extraction), full serialization (GTIN/NTIN/PPN data matrix, aggregation), and ICH- and EU-pharmacopoeia-compliant quality control. Annual production capacity reaches up to 1 million sterile vials. The proprietary generic portfolio spans nine SKUs across oncology (Bortezomib), obstetrics (Atosiban, Carbetocin), antifungal (Anidulafungin, Micafungin), cardiology (Levosimendan), anesthesia (Dexmedetomidine, Sugammadex), and bone metastases (Zoledronic Acid). Active R&D pipeline includes Semaglutide finished dosage form, Caspofungin lyophilized form improvement, Isavuconazole capsules, and a Sugammadex sterile injection technology program.

Revenue is generated through four streams: contract manufacturing (batch production for pharma clients), contract development (validation batches, stability studies, registration documentation), product licensing (transfer of EMA/ICH-compliant dossiers to client markets), and direct sales of proprietary generics. The GTM is enterprise field sales to pharmaceutical companies, supported by active participation in international events (CPhI, ACHEMA, euroPLX, WHX Dubai, BIOPLUS-INTERPHEX) and a channel partner network spanning Europe, Middle East, Africa, and Southeast Asia. R&D partnerships include the Latvian Organic Synthesis Institute, the FBMTKC competence center, SIA Cellboxlab (COMPETE/Ozempic project), ProJect Pharmaceutics, and the LAĶIFA industry association. The company employs 100+ professionals led by CEO and board member Vitālijs Skrīvelis.

Short descriptiontext

PharmIdea is a Latvia-headquartered, EU GMP-certified CDMO and proprietary generics manufacturer specializing in sterile injectable drugs in vials, serving pharmaceutical companies across 60+ countries with contract manufacturing, licensing, and nine in-house generic products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOlaine, Latvia
HQ citystring
Olaine
HQ countrystring
Latvia
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile drug manufacturing, contract pharmaceutical manufacturing, generic injectable products, lyophilization services, GMP certified manufacturing
Industry2 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Contract Sterile Pharmaceutical Manufacturing
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Contract manufacturing services (CMO/CDMO)
TypeProfessional Services
Description

PharmIdea manufactures generic sterile medications in vials for pharmaceutical companies on a contract basis. Services include technology development, validation batch production, stability studies, and documentation preparation for drug registration.

pharmidea.lv
2Product licensing
TypeLicensing Royalties
Description

Licensing of finished pharmaceutical products with ready-to-use technical documentation for sterile drug forms compliant with EMA and ICH guidelines, enabling clients to register products in their markets.

pharmidea.lv
3Investigational drug development and manufacturing
TypeProfessional Services
Description

Development services for investigational medicinal products (IMP) including formulation optimization, technology development, and manufacturing for Phase I-III clinical trials, including batch packaging and labeling.

pharmidea.lv
4Finished pharmaceutical product sales
TypeHardware Sales
Description

Direct sales of proprietary generic sterile medications in therapeutic areas including oncology, obstetrics, antifungal, cardiology, and anesthesia.

pharmidea.lv
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Visual Control and Packaging Operator position
ModelOtherBilling cadenceMonthly
Notes

Salary up to 1300 EUR/month gross, plus transport expense compensation and health insurance after probation period.

pharmidea.lv
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

PharmIdea is a Latvia-based pharmaceutical company that develops and manufactures sterile generic drugs in vials, offering a portfolio of nine injectable products across oncology, obstetrics, antifungal, cardiology, and anesthesia therapeutic areas. The company also provides contract development, contract manufacturing, and product licensing services for pharmaceutical clients globally, with production capacity up to 1 million sterile vials annually using lyophilization, aseptic filling, and autoclaving technologies. All operations are conducted under EU GMP certification with regulatory approvals from 14+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Production capacity up to 1 million sterile vials per year
+2 more records
Product overview1 text field

PharmIdea is a Latvia-based pharmaceutical company specializing in the development and manufacturing of sterile generic drugs in vials. The company offers a portfolio of 9 generic pharmaceutical products spanning therapeutic areas including oncology (Bortezomib), obstetrics (Atosiban, Carbetocin), antifungal treatments (Anidulafungin, Micafungin), cardiology (Levosimendan), anesthesia (Dexmedetomidine, Sugammadex), and bone metastases management (Zoledronic Acid). Alongside its product portfolio, PharmIdea provides comprehensive contract services including contract manufacturing (utilizing lyophilization, aseptic filling, and autoclaving technologies with capacity up to 1 million sterile vials annually), contract development, product licensing with EMA/ICH compliant documentation, serialization, and investigational medicinal product development for clinical trials. The company is the only sterile drug manufacturer in Latvia and operates as a CDMO/CMO serving international markets across 60+ countries.

Product and service15 records
1Bortezomib
CategoryGeneric pharmaceutical product
Description

Antineoplastic agent (powder for solution for injection at 3.5 mg) for the treatment of multiple myeloma and mantle cell lymphoma.

2Atosiban
CategoryGeneric pharmaceutical product
Description

Tocolytic agent (solution for injection 6.75 mg/0.9 ml and concentrate for solution for infusion 37.5 mg/5 ml) indicated to delay imminent pre-term birth.

3Carbetocin
CategoryGeneric pharmaceutical product
Description

Oxytocin analog (solution for injection at 100 mcg/ml) for the prevention of postpartum haemorrhage due to uterine atony after Caesarean section under epidural or spinal anaesthesia.

4Anidulafungin
CategoryGeneric pharmaceutical product
Description

Systemic antifungal agent (powder for concentrate for solution for infusion at 100 mg) for the treatment of invasive candidiasis in adults.

5Micafungin
CategoryGeneric pharmaceutical product
Description

Echinocandin antifungal (powder for concentrate for solution for infusion at 50 mg) for the treatment of invasive candidiasis in adults and children.

6Levosimendan
CategoryGeneric pharmaceutical product
Description

Calcium sensitizer (concentrate for solution for infusion at 2.5 mg/ml) for the treatment of acutely decompensated severe chronic heart failure.

7Dexmedetomidine
CategoryGeneric pharmaceutical product
Description

Sedative agent (concentrate for solution for infusion at 100 µg/ml in 200 µg/2 ml, 400 µg/4 ml, and 1000 µg/10 ml presentations) for sedation of intubated patients in intensive care units and sedation of non-intubated patients before diagnostic or surgical procedures.

8Sugammadex
CategoryGeneric pharmaceutical product
Description

Selective relaxant binding agent (solution for injection at 100 mg/ml available in 200 mg/2 ml and 500 mg/5 ml presentations) for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.

9Zoledronic Acid
CategoryGeneric pharmaceutical product
Description

Bisphosphonate (concentrate for solution for infusion at 4 mg/5 ml) for the treatment of hypercalcemia of malignancy and prevention of skeletal-related events in patients with progressive bone metastases.

10Contract Manufacturing Services
CategoryContract manufacturing service
Description

Production of generic drugs in sterile vials using lyophilization (freeze-drying), aseptic filling, and autoclaving (terminal steam sterilization) technologies. Production capacity reaches up to 1 million sterile vials per year.

11Contract Development Services
CategoryContract development service
Description

Full product lifecycle services including qualification of active substance, technology development, production of validation batches, stability studies, and preparation of documentation for drug registration in European and other global markets.

12Product Licensing
CategoryLicensing service
Description

Ready-to-use technical documentation for sterile drug forms compliant with EMA and ICH guidelines, with support for documentation adaptation according to client country requirements for product licensing.

13Serialization Services
CategorySerialization service
Description

Serialization number generation and data matrix code assignment in GTIN/NTIN/PPN formats, with printing on cardboard packaging and aggregation of packaging, transport boxes, and pallets.

14Investigational Medicinal Products (IMP) Development
CategoryClinical trial service
Description

Optimization of investigational medicinal product formulations, technology development in laboratory and commercial manufacturing conditions, and preparation of technical documentation for Phase I-III clinical trials, including batch packaging and labeling.

15Technology Transfer
CategoryTechnology transfer service
Description

Transfer of production technology and analytical methods to/from third-party manufacturers in accordance with ICH and EU pharmacopoeia requirements.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
1Latvijas Organiskās sintēzes institūts (Latvian Organic Synthesis Institute)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research and development partnership with Latvia's leading organic synthesis institute for pharmaceutical development collaboration.

pharmidea.lv
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner for pharmaceutical products in certain markets.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Pharmaceutical distribution partner.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner in Vietnam market.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Pharmaceutical distribution partner.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner in Middle East markets.

7AV Medical CZ s.r.o.
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Medical products distribution partner.

pharmidea.lv
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pharmaceutical manufacturing partnership.

9LIDDS AB
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Pharmaceutical technology partnership.

pharmidea.lv
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration partner for COMPETE project on Ozempic generic drug quality assessment using in vitro test systems (Organs-on-Chips vs traditional test systems). Project funded by ERDF.

11SIA Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centrs (FBMTKC)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Competence center partnership for multiple research projects including Sugamadex sterile injection technology development, Caspofungin lyophilized form stability improvement, Isavuconazole capsule formulation, and Semaglutide finished dosage form technology development. Multiple projects funded by Recovery Fund.

pharmidea.lv
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership in Latvian chemistry and pharmacy industry association network project for life sciences sector development, internationalization, and export promotion. Part of Recovery Fund project 5.1.1.2.i.0/3/24/A/CFLA/003.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Meeting with Samsung Biologics biotechnology division to discuss potential collaboration opportunities. Samsung Biologics is one of the world's largest contract manufacturing companies in the biopharmaceutical industry.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Meeting with Celltrion Healthcare to discuss potential biosimilar product collaboration opportunities. Celltrion specializes in global marketing, distribution and sales of biological products including biosimilars.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Aenova is a European CDMO offering sterile liquid and lyophilized manufacturing for generics and branded pharma, comparable in services, customer profile, and geographic scope.

2Recipharm
TypeDirect peer
Description

Recipharm is a European CDMO with significant sterile injectable fill-finish capacity serving global pharma, directly comparable to PharmIdea's CDMO model and customer base in sterile generics manufacturing.

TypeDirect peer
Description

Almac offers sterile commercial manufacturing and contract development services for global pharma, including lyophilization, with comparable regulatory documentation and licensing services.

TypeBroad incumbent
Description

Catalent is a large global CDMO with extensive sterile injectable capabilities; comparable to PharmIdea in service offering but operates at vastly greater scale and breadth.

TypeDirect peer
Description

Hovione provides CDMO services including sterile injectable manufacturing and particle engineering for global pharma, overlapping with PharmIdea's aseptic fill-finish and lyophilization offerings.

TypeRegional player
Description

Olainfarm is a Latvian pharmaceutical manufacturer; same domestic market and overlapping therapeutic/generic portfolio, providing a regional benchmark for PharmIdea's domestic positioning.

TypeDirect peer
Description

Vetter specializes in aseptic filling of sterile injectables including lyophilization, directly mirroring PharmIdea's core technological offering for global pharma clients.

8Fareva
TypeDirect peer
Description

Fareva is a French-headquartered CDMO with sterile injectable manufacturing capabilities serving European and international pharma, directly comparable to PharmIdea's model.

TypeRegional player
Description

Grindeks is the largest Latvian pharmaceutical manufacturer with export reach, comparable as a same-country peer operating in generic injectable and finished dosage forms.

TypeDirect peer
Description

Siegfried is a Swiss CDMO with sterile manufacturing of APIs and finished dosage forms, including injectables — comparable to PharmIdea's offering across the full pharma value chain.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PharmIdea

Contract Sterile Pharmaceutical Manufacturingpharmidea.lv

PharmIdea is a Latvia-headquartered, EU GMP-certified CDMO and proprietary generics manufacturer specializing in sterile injectable drugs in vials, serving pharmaceutical companies across 60+ countries with contract manufacturing, licensing, and nine in-house generic products.

What PharmIdea does

PharmIdea (legal entity SIA PHARMIDEA) is a Latvia-headquartered, privately held pharmaceutical manufacturer and CDMO/CMO that is the only producer of sterile drugs in vials in Latvia. Founded in 2005 with EU GMP certification achieved in 2010, the company has accumulated 15+ years of sterile drug technology development, registration documentation, and manufacturing experience, with regulatory approvals from the European Union plus 14+ additional countries including Saudi Arabia, UAE, South Korea, Canada, Russia, Thailand, Philippines, Malaysia, Kuwait, and Jordan. Its products are registered and distributed in 60+ countries across Europe, Africa, Asia, and the Americas.

The technology stack centers on three sterile manufacturing platforms — lyophilization (freeze-drying), aseptic filling for 2-30 ml vials, and terminal steam sterilization (autoclaving) — supplemented by in-house analytical capabilities (HPLC, UV/VIS spectrophotometry, SCF extraction), full serialization (GTIN/NTIN/PPN data matrix, aggregation), and ICH- and EU-pharmacopoeia-compliant quality control. Annual production capacity reaches up to 1 million sterile vials. The proprietary generic portfolio spans nine SKUs across oncology (Bortezomib), obstetrics (Atosiban, Carbetocin), antifungal (Anidulafungin, Micafungin), cardiology (Levosimendan), anesthesia (Dexmedetomidine, Sugammadex), and bone metastases (Zoledronic Acid). Active R&D pipeline includes Semaglutide finished dosage form, Caspofungin lyophilized form improvement, Isavuconazole capsules, and a Sugammadex sterile injection technology program.

Revenue is generated through four streams: contract manufacturing (batch production for pharma clients), contract development (validation batches, stability studies, registration documentation), product licensing (transfer of EMA/ICH-compliant dossiers to client markets), and direct sales of proprietary generics. The GTM is enterprise field sales to pharmaceutical companies, supported by active participation in international events (CPhI, ACHEMA, euroPLX, WHX Dubai, BIOPLUS-INTERPHEX) and a channel partner network spanning Europe, Middle East, Africa, and Southeast Asia. R&D partnerships include the Latvian Organic Synthesis Institute, the FBMTKC competence center, SIA Cellboxlab (COMPETE/Ozempic project), ProJect Pharmaceutics, and the LAĶIFA industry association. The company employs 100+ professionals led by CEO and board member Vitālijs Skrīvelis.

PharmIdea firmographics

Firmographics
Name
PharmIdea
Legal name
SIA PHARMIDEA
Website
https://pharmidea.lv
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
PharmIdea is a Latvia-headquartered, EU GMP-certified CDMO and proprietary generics manufacturer specializing in sterile injectable drugs in vials, serving pharmaceutical companies across 60+ countries with contract manufacturing, licensing, and nine in-house generic products.
Ownership category
akta.pro rank

PharmIdea industry classification

Industry
Product category
Contract Sterile Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)

Keywords

  • Sterile drug manufacturing
  • Contract pharmaceutical manufacturing
  • Generic injectable products
  • Lyophilization services
  • GMP certified manufacturing

Where PharmIdea is headquartered

Location

Headquarters

HQ city
Olaine
HQ country
Latvia
HQ region
Europe

Offices1 record

Markets served

PharmIdea business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract manufacturing services (CMO/CDMO): PharmIdea manufactures generic sterile medications in vials for pharmaceutical companies on a contract basis. Services include technology development, validation batch production, stability studies, and documentation preparation for drug registration.
  2. Product licensing: Licensing of finished pharmaceutical products with ready-to-use technical documentation for sterile drug forms compliant with EMA and ICH guidelines, enabling clients to register products in their markets.
  3. Investigational drug development and manufacturing: Development services for investigational medicinal products (IMP) including formulation optimization, technology development, and manufacturing for Phase I-III clinical trials, including batch packaging and labeling.
  4. Finished pharmaceutical product sales: Direct sales of proprietary generic sterile medications in therapeutic areas including oncology, obstetrics, antifungal, cardiology, and anesthesia.

Pricing tiers

ModelBillingPrice
OtherMonthlyVisual Control and Packaging Operator position

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

PharmIdea product offering

Product offering

Core offering

PharmIdea is a Latvia-based pharmaceutical company that develops and manufactures sterile generic drugs in vials, offering a portfolio of nine injectable products across oncology, obstetrics, antifungal, cardiology, and anesthesia therapeutic areas. The company also provides contract development, contract manufacturing, and product licensing services for pharmaceutical clients globally, with production capacity up to 1 million sterile vials annually using lyophilization, aseptic filling, and autoclaving technologies. All operations are conducted under EU GMP certification with regulatory approvals from 14+ countries.

Product overview

PharmIdea is a Latvia-based pharmaceutical company specializing in the development and manufacturing of sterile generic drugs in vials. The company offers a portfolio of 9 generic pharmaceutical products spanning therapeutic areas including oncology (Bortezomib), obstetrics (Atosiban, Carbetocin), antifungal treatments (Anidulafungin, Micafungin), cardiology (Levosimendan), anesthesia (Dexmedetomidine, Sugammadex), and bone metastases management (Zoledronic Acid). Alongside its product portfolio, PharmIdea provides comprehensive contract services including contract manufacturing (utilizing lyophilization, aseptic filling, and autoclaving technologies with capacity up to 1 million sterile vials annually), contract development, product licensing with EMA/ICH compliant documentation, serialization, and investigational medicinal product development for clinical trials. The company is the only sterile drug manufacturer in Latvia and operates as a CDMO/CMO serving international markets across 60+ countries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bortezomib Antineoplastic agent (powder for solution for injection at 3.5 mg) for the treatment of multiple myeloma and mantle cell lymphoma.
  • Atosiban Tocolytic agent (solution for injection 6.75 mg/0.9 ml and concentrate for solution for infusion 37.5 mg/5 ml) indicated to delay imminent pre-term birth.
  • Carbetocin Oxytocin analog (solution for injection at 100 mcg/ml) for the prevention of postpartum haemorrhage due to uterine atony after Caesarean section under epidural or spinal anaesthesia.
  • Anidulafungin Systemic antifungal agent (powder for concentrate for solution for infusion at 100 mg) for the treatment of invasive candidiasis in adults.
  • Micafungin Echinocandin antifungal (powder for concentrate for solution for infusion at 50 mg) for the treatment of invasive candidiasis in adults and children.
  • Levosimendan Calcium sensitizer (concentrate for solution for infusion at 2.5 mg/ml) for the treatment of acutely decompensated severe chronic heart failure.
  • Dexmedetomidine Sedative agent (concentrate for solution for infusion at 100 µg/ml in 200 µg/2 ml, 400 µg/4 ml, and 1000 µg/10 ml presentations) for sedation of intubated patients in intensive care units and sedation of non-intubated patients before diagnostic or surgical procedures.
  • Sugammadex Selective relaxant binding agent (solution for injection at 100 mg/ml available in 200 mg/2 ml and 500 mg/5 ml presentations) for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.
  • Zoledronic Acid Bisphosphonate (concentrate for solution for infusion at 4 mg/5 ml) for the treatment of hypercalcemia of malignancy and prevention of skeletal-related events in patients with progressive bone metastases.
  • Contract Manufacturing Services Production of generic drugs in sterile vials using lyophilization (freeze-drying), aseptic filling, and autoclaving (terminal steam sterilization) technologies. Production capacity reaches up to 1 million sterile vials per year.
  • Contract Development Services Full product lifecycle services including qualification of active substance, technology development, production of validation batches, stability studies, and preparation of documentation for drug registration in European and other global markets.
  • Product Licensing Ready-to-use technical documentation for sterile drug forms compliant with EMA and ICH guidelines, with support for documentation adaptation according to client country requirements for product licensing.
  • Serialization Services Serialization number generation and data matrix code assignment in GTIN/NTIN/PPN formats, with printing on cardboard packaging and aggregation of packaging, transport boxes, and pallets.
  • Investigational Medicinal Products (IMP) Development Optimization of investigational medicinal product formulations, technology development in laboratory and commercial manufacturing conditions, and preparation of technical documentation for Phase I-III clinical trials, including batch packaging and labeling.
  • Technology Transfer Transfer of production technology and analytical methods to/from third-party manufacturers in accordance with ICH and EU pharmacopoeia requirements.

Quantifiable outcome

  • Production capacity up to 1 million sterile vials per year
  • +2 more outcomes

Companies that use PharmIdea

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

PharmIdea technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

PharmIdea partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered core and minor.

  • Latvijas Organiskās sintēzes institūts (Latvian Organic Synthesis Institute)coreStrategic or Co-development PartnerResearch and development partnership with Latvia's leading organic synthesis institute for pharmaceutical development collaboration.
  • Selectchemie AGminorChannel Partner/ Reseller/ DistributorDistribution partner for pharmaceutical products in certain markets.
  • Logenex Pharm GmbHminorChannel Partner/ Reseller/ DistributorPharmaceutical distribution partner.
  • Viet PhapminorChannel Partner/ Reseller/ DistributorDistribution partner in Vietnam market.
  • Austell Laboratories LtdminorChannel Partner/ Reseller/ DistributorPharmaceutical distribution partner.
  • Kuwait Saudi Pharmaceutical Industries Co.minorChannel Partner/ Reseller/ DistributorDistribution partner in Middle East markets.
  • AV Medical CZ s.r.o.minorChannel Partner/ Reseller/ DistributorMedical products distribution partner.
  • Polfa SA TarchominminorStrategic or Co-development PartnerPharmaceutical manufacturing partnership.
  • LIDDS ABminorStrategic or Co-development PartnerPharmaceutical technology partnership.
  • CellboxlabcoreStrategic or Co-development PartnerResearch collaboration partner for COMPETE project on Ozempic generic drug quality assessment using in vitro test systems (Organs-on-Chips vs traditional test systems). Project funded by ERDF.
  • SIA Farmācijas, biomedicīnas un medicīnas tehnoloģiju kompetences centrs (FBMTKC)coreStrategic or Co-development PartnerCompetence center partnership for multiple research projects including Sugamadex sterile injection technology development, Caspofungin lyophilized form stability improvement, Isavuconazole capsule formulation, and Semaglutide finished dosage form technology development. Multiple projects funded by Recovery Fund.
  • Latvijas Ķīmijas un farmācijas ismene asociācija (LAĶIFA)coreStrategic or Co-development PartnerPartnership in Latvian chemistry and pharmacy industry association network project for life sciences sector development, internationalization, and export promotion. Part of Recovery Fund project 5.1.1.2.i.0/3/24/A/CFLA/003.
  • Samsung BiologicsminorStrategic or Co-development PartnerMeeting with Samsung Biologics biotechnology division to discuss potential collaboration opportunities. Samsung Biologics is one of the world's largest contract manufacturing companies in the biopharmaceutical industry.
  • Celltrion HealthcareminorStrategic or Co-development PartnerMeeting with Celltrion Healthcare to discuss potential biosimilar product collaboration opportunities. Celltrion specializes in global marketing, distribution and sales of biological products including biosimilars.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

PharmIdea competitors and assessment

Company assessment

Direct peers

  • Aenova: Aenova is a European CDMO offering sterile liquid and lyophilized manufacturing for generics and branded pharma, comparable in services, customer profile, and geographic scope.
  • Recipharm: Recipharm is a European CDMO with significant sterile injectable fill-finish capacity serving global pharma, directly comparable to PharmIdea's CDMO model and customer base in sterile generics manufacturing.
  • Almac Group: Almac offers sterile commercial manufacturing and contract development services for global pharma, including lyophilization, with comparable regulatory documentation and licensing services.
  • Hovione: Hovione provides CDMO services including sterile injectable manufacturing and particle engineering for global pharma, overlapping with PharmIdea's aseptic fill-finish and lyophilization offerings.
  • Vetter Pharma: Vetter specializes in aseptic filling of sterile injectables including lyophilization, directly mirroring PharmIdea's core technological offering for global pharma clients.
  • Fareva: Fareva is a French-headquartered CDMO with sterile injectable manufacturing capabilities serving European and international pharma, directly comparable to PharmIdea's model.
  • Siegfried Holding: Siegfried is a Swiss CDMO with sterile manufacturing of APIs and finished dosage forms, including injectables — comparable to PharmIdea's offering across the full pharma value chain.

Broad incumbents

  • Catalent: Catalent is a large global CDMO with extensive sterile injectable capabilities; comparable to PharmIdea in service offering but operates at vastly greater scale and breadth.

Regional players

  • Olainfarm: Olainfarm is a Latvian pharmaceutical manufacturer; same domestic market and overlapping therapeutic/generic portfolio, providing a regional benchmark for PharmIdea's domestic positioning.
  • Grindeks: Grindeks is the largest Latvian pharmaceutical manufacturer with export reach, comparable as a same-country peer operating in generic injectable and finished dosage forms.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

PharmIdea social profiles

Digital presence

PharmIdea financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PharmIdea leadership team

Management profile

Number of profiles

Profiles11 records

PharmIdea funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PharmIdea M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmIdea

What does PharmIdea do?

PharmIdea is a Latvia-based pharmaceutical company that develops and manufactures sterile generic drugs in vials, offering a portfolio of nine injectable products across oncology, obstetrics, antifungal, cardiology, and anesthesia therapeutic areas. The company also provides contract development, contract manufacturing, and product licensing services for pharmaceutical clients globally, with production capacity up to 1 million sterile vials annually using lyophilization, aseptic filling, and autoclaving technologies. All operations are conducted under EU GMP certification with regulatory approvals from 14+ countries.

Is PharmIdea a public or private company?

PharmIdea is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was PharmIdea founded?

PharmIdea was founded in 2010. It employs 11 to 50 people.

Where is PharmIdea based?

PharmIdea is headquartered in Olaine, Latvia, in the Europe region.

How does PharmIdea make money?

Four revenue lines are on record. Contract manufacturing services (CMO/CDMO) is the primary driver. The others are product licensing, investigational drug development and manufacturing and finished pharmaceutical product sales.

Who are PharmIdea's main competitors?

Direct peers on record are Aenova, Recipharm, Almac Group, Hovione, Vetter Pharma, Fareva and Siegfried Holding. Catalent is listed as a broad incumbent. Regional players are Olainfarm and Grindeks.

Does PharmIdea have an API?

No public API is recorded for PharmIdea.

What industry is PharmIdea in?

PharmIdea's product category is Contract Sterile Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals